Drug Trial Radar · NCT06409481
Pharmacovigilance Assessment of Reporting of Cardiovascular Adverse Events With Antineoplastic Agents (PARCA)
Last checked: Nov 20, 2026Latest source record: May 10, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
800,000
Planned (sponsor's estimate)
Start
Jun 1, 2024
Primary completion
Jun 30, 2024
Study completion Oct 30, 2024
Sponsor
- Lead sponsor
- The First Affiliated Hospital of Xinxiang Medical CollegeAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 10, 2024
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this observational study is to explore and analyze reports of cardiac or vascular adverse events linked to the administration of antineoplastic agents among patients diagnosed with tumors represented by advanced non-small cell lung cancer. The study leverages pharmacovigilance databases such as the World Health Organization (WHO) database (VigiBase), FDA Adverse Event Reporting System (FAERS), and others to gather individual safety case reports for analysis.
Conditions
- Cardiovascular Diseases
- Cardiac Diseases
- Vascular Diseases
- Cancer
Interventions
Antineoplastic AgentsDrug
small-molecule kinase inhibitors, immune checkpoint inhibitors, monoclonal antibodies, cytotoxic drugs, and other therapeutics
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cardio-vascular toxicity of antineoplastic agentsTime frame: Case reported in VigiBase, FAERS and other pharmacovigilance databases of individual safety case reports to 12/31/2024
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.